Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Esther Kissling, Mariëtte Hooiveld, Virginia Martin et al.|Eurosurveillance|2021Cited by 55
Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, EuropeKimberley Benschop, Suzan D. Pas, Robert Dyrdak et al.|Emerging infectious diseases|2021Cited by 51
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohortEsther Kissling, Francisco Pozo, Silke Buda et al.|Eurosurveillance|2019Cited by 48
2015/16 I‐<scp>MOVE</scp>/I‐<scp>MOVE</scp>+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among childrenEsther Kissling, Marta Valenciano, Francisco Pozo et al.|Influenza and Other Respiratory Viruses|2017Cited by 37
Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)Esther Kissling, Marta Valenciano, Francisco Pozo et al.|Vaccine X|2019Cited by 36